Investors / Double Point Ventures
Double Point Ventures
Venture capital
Double Point Ventures is a healthcare-focused investment firm that backs companies in therapeutics, diagnostics and devices, and digital health and healthcare services. It provides capital alongside industry expertise, operational guidance, and a network to support company growth.
Invests inHealthcare & Biotech
In its own wordshealthcarebiotechtherapeuticsdiagnosticsdigital healthlife sciences
Your fit with Double Point Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsDouble Point Ventures lists 13 checked portfolio companies on its own site and is named in 3 funding rounds, 2 of them as lead. Its most frequent entry is Series A, 67% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 100% of its companies are based in United States. It invests most often alongside Agent Capital, Casdin Capital and Civilization Ventures.
Counts come from funding rounds that name Double Point Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Double Point Ventures' whole history. Rounds on record name 3 companies; its own site lists 13. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundDouble Point Ventures does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 67% |
| Series B | 0% |
| Growth | 33% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 1 |
| '26 | 2 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 33th | 13 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 94th | 23% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 20th | 1 country |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Agent Capital | 2 |
| Casdin Capital | 2 |
| Civilization Ventures | 2 |
| DigiTx Partners | 2 |
| Foresite Capital | 2 |
| Olive Tree Capital | 2 |
| ARCH Venture Partners | 1 |
| ARK Venture Fund | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers13100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Double Point Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Double Point Ventures| Date | Company | Stage |
|---|---|---|
| 12 May 2026 | Series C+ | |
| 28 Apr 2026 | Series A Led | |
| 6 Nov 2025 | Series A Led |
Round details for Double Point Ventures
Amounts, full round histories and every co-investor in Double Point Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
13 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Cerevance develops therapies for neurodegenerative disorders, including Parkinson's disease. | Healthcare & Biotech | May 2026Series C+ | Page + round | |
| Cleerly analyzes and treats heart disease using personalized analysis and treatment methods. | Healthcare & Biotech | Portfolio page | ||
| DermBiont is developing a treatment for skin disorders such as Melasma and hyperpigmentation. | Healthcare & Biotech | Portfolio page | ||
| Eko creates digital stethoscopes and provides AI disease detection and telehealth solutions | Healthcare & Biotech | Portfolio page | ||
| Foresight Diagnostics develops and delivers innovative diagnostic tests that combine precision genomics and cutting-edge bioinformatics to advance cancer drug development and patient care. | Healthcare & Biotech | Portfolio page | ||
| GEMMABio is a biotechnology company developing transformative therapies for rare diseases. | Healthcare & Biotech | Portfolio page | ||
| The company is advancing innovative genetic therapies designed to address the underlying cause of neurometabolic disorders. | Healthcare & Biotech | Portfolio page | ||
| Jana Care develops a smartphone-enabled health testing system for monitoring health from home | Healthcare & Biotech | Portfolio page | ||
| Lighthouse Pharmaceuticals develops precision therapeutics for major unmet medical needs, including treatments for Alzheimer's disease. | Healthcare & Biotech | Apr 2026Series A | Page + round | |
| Lumos Pharma is a clinical stage, biopharmaceutical company developing therapeutics for rare diseases. | Healthcare & Biotech | Portfolio page | ||
| Rinascera Therapeutics develops transformative therapies for rare genetic skin diseases. | Healthcare & Biotech | Portfolio page | ||
| Synchron builds implantable Brain-Computer Interfaces to protect what makes you human. | Healthcare & Biotech | Nov 2025Series A | Page + round | |
| Umoja Biopharma develops in vivo CAR T cell therapies for the treatment of cancers and other conditions. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- doublepointventures.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 6 Nov 2025
- Companies checked
- 13
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Double Point Ventures' profile as data
Pull Double Point Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/doublepointventures.com
# also
GET /v1/firms/doublepointventures.com/portfolio
GET /v1/firms/doublepointventures.com/coinvestors
GET /v1/firms/doublepointventures.com/news